Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology meeting in San Francisco.

In 46 evaluable patients in the stage 1 cohort, subcutaneous SL-701 plus GM-CSF and imiquimod led to a disease control rate (DCR) of 35% and an overall response rate (ORR) of 2%, including 1 partial response and 15 cases of stable disease. Median overall survival (OS) was 10.9 months, with a 12-month OS rate of 36%...